Inactive Instrument

Analyst Reco. Conformis, Inc.

Equities

Oppenheimer Downgrades ConforMIS to Perform From Outperform, Removes $6 Price Target	23-05-09	MT
Oppenheimer Adjusts ConforMIS Price Target to $8 From $1.25, Maintains Outperform Rating	22-11-11	MT
Conformis iTotal® CR Knee Replacement System Awarded “7A” Performance Rating from the U.K.’s Orthopaedic Data Evaluation Panel	22-02-24	AQ
Conformis : iTotal® CR Knee Replacement System Awarded “5A” Rating from the Orthopaedic Data Evaluation Panel in the United Kingdom	20-02-19	AQ
Conformis iTotal CR Knee Replacement System Awarded “3A” Rating from the Orthopaedic Data Evaluation Panel in the United Kingdom	18-03-01	GL

No results for this search